Verity Pharmaceuticals
- Company typePrivate
- Founded2016
- HeadquartersMississauga, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Verity Pharmaceuticals firmographics
Firmographics- Name
- Verity Pharmaceuticals
- Legal name
- Verity Pharmaceuticals, Inc.
- Website
- https://veritypharma.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Verity Pharmaceuticals industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Specialty Pharmaceutical Distributors (HLAIAJAB), Nephrology & Urology Pharmaceuticals (HLAIAAAM)
Keywords
Where Verity Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Mississauga
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
Verity Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D
Revenue model
- Product Licensing and Commercialization: Verity Pharma generates revenue through exclusive licensing agreements to commercialize pharmaceutical products in specified territories. The company receives commercial rights to products from partners and generates revenue through product sales and commercialization activities. In January 2024, Lipocine and Verity entered into an exclusive license agreement where Verity gained commercial rights to TLANDO in the US and Canada, with Lipocine receiving license fee payments.
- Product Promotion Services: Verity provides promotional services for pharmaceutical products in exchange for revenue sharing or promotional fees. The company promotes products from partners (such as Akynzeo, Valchlor from Helsinn, Natesto from Acerus) in specific markets like Puerto Rico, leveraging its existing commercial footprint and healthcare network while partners maintain control of distribution, market access, and regulatory activities.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Verity Pharmaceuticals product offering
Product offeringCore offering
Verity Pharmaceuticals commercializes specialty prescription pharmaceuticals in urology, oncology, infectious disease, and men's/women's health across the US, Canada, and Puerto Rico. The company in-licenses or acquires late-stage/in-market pharmaceutical products from global manufacturers and commercializes them through a focused direct sales force targeting healthcare providers. Core products include TLANDO (oral testosterone), TRELSTAR (prostate cancer), VERITY-BCG (bladder cancer), Zeulide Depot, and IVOZFO, with additional promotional partnerships in Puerto Rico.
Product overview
Verity Pharmaceuticals is a specialty pharmaceutical company that commercializes prescription therapeutics through licensing and distribution partnerships. The company operates across three geographic markets (U.S., Canada, and Puerto Rico) and focuses on therapeutic areas including urology, oncology, infectious disease, and men's/women's health. The product portfolio includes proprietary brands (TLANDO, TRELSTAR, VERITY-BCG, Zeulide Depot, IVOZFO) as well as partnered brands promoted in Puerto Rico (AKYNZEO, VALCHLOR, NATESTO, VIBATIV). The company does not develop drugs internally but acquires late-stage or in-market products from global pharmaceutical partners and commercializes them through its established infrastructure.
Differentiator
Problem solved
Functional benefit
Products and services
- TLANDO Oral testosterone replacement therapy (TRT) approved for adult males with conditions associated with deficiency or absence of endogenous testosterone, including primary and hypogonadotropic hypogonadism. Developed using Lipocine's proprietary Lip'ral drug delivery technology platform. Commercialized by Verity in the US and Canada under exclusive license.
- TRELSTAR Gonadotropin-releasing hormone (GnRH) agonist indicated for the palliative treatment of advanced prostate cancer. Available in 1, 3, and 6-month sustained-release formulations. Commercialized by Verity in the US under exclusive 20-year extendable agreement with Debiopharm.
- VERITY-BCG Bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer. Adjuvant therapy after transurethral resection of non-muscle-invasive bladder cancer. Manufactured by Serum Institute of India and commercialized by Verity in Canada.
- Zeulide Depot Leuprolide acetate for depot suspension, a Luteinizing Hormone-Releasing Hormone (LHRH) analog indicated for the palliative treatment of advanced and/or metastatic prostate cancer. Uses patented microsphere technology for sustained release. Commercialized by Verity in Canada.
- IVOZFO Intravenous fosfomycin injection, a first-in-class IV antibiotic with broad spectrum bactericidal activity against Gram-negative and Gram-positive organisms including MDR strains. Indicated for complicated urinary tract infections, osteomyelitis, bacterial meningitis, bacteremia, and nosocomial lower respiratory tract infections. Licensed from InfectoPharm and commercialized in Canadian hospital market.
- AKYNZEO Fixed combination of 5-HT3 and NK1 receptor antagonists (netupitant/palonosetron) approved for the prevention of chemotherapy-induced acute and delayed nausea and vomiting. Available in oral capsule and injectable formulations. Promoted by Verity in Puerto Rico through partnership with Helsinn Therapeutics.
- VALCHLOR Topical mechlorethamine gel (0.016%) indicated for the treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy. Promoted by Verity in Puerto Rico through partnership with Helsinn Therapeutics.
- NATESTO Testosterone nasal gel for testosterone replacement therapy. Promoted by Verity in Puerto Rico through commercial agreement with Acerus Pharmaceuticals, leveraging Verity's existing commercial footprint and healthcare network.
- VIBATIV FDA-approved injectable anti-infective (telavancin) designed to treat serious infections including hospital-acquired and ventilator-associated pneumonia, including those from MRSA. Promoted by Verity in Puerto Rico through partnership with Cumberland Pharmaceuticals.
Quantifiable outcome
- VERITY-BCG resolved Canada's multi-year BCG drug shortage, making Canada the first country in the western world to solve the shortage crisis
- +2 more outcomes
Companies that use Verity Pharmaceuticals
Customer profileSegments3 records
Ideal customer profiles2 records
Verity Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Verity Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, minor and major.
- LipocinecoreIn January 2024, Lipocine and Verity Pharma entered into an exclusive license agreement under which Verity Pharma gained commercial rights to TLANDO (testosterone replacement therapy) in the United States and Canada. TLANDO is the first and only oral TRT option approved by the FDA that does not require dose titration. Commercialization was transitioned to Verity Pharma effective February 1, 2024. Lipocine received an $11 million license fee with tranches of $5M (received), $2.5M (due January 2025), and $1M (due January 2026). Verity Pharma filed an NDS for TLANDO in Canada in June 2025.
- Cumberland PharmaceuticalsminorCumberland Pharmaceuticals and Verity Pharmaceuticals announced the launch of VIBATIV (telavancin) injection in Puerto Rico. Cumberland is responsible for product supply while Verity commercializes and promotes the product in the local market. VIBATIV is an FDA-approved injectable anti-infective designed to treat serious infections including hospital-acquired and ventilator-associated pneumonia, including those from MRSA.
- Helsinn TherapeuticsminorVerity Pharmaceuticals and Helsinn Therapeutics signed an exclusive agreement for the promotion of Akynzeo (netupitant/palonosetron) and Valchlor (mechlorethamine gel) in Puerto Rico. Akynzeo is the first and only 5-HT3 and NK1 receptor antagonists fixed combination for chemotherapy-induced nausea and vomiting prevention. Valchlor is indicated for topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma.
- Acerus PharmaceuticalsminorVerity Pharmaceuticals formed a commercial agreement with Acerus Pharmaceuticals for exclusive rights to promote Natesto (testosterone nasal gel) in Puerto Rico. Verity promotes Natesto to healthcare professionals throughout Puerto Rico leveraging its existing commercial footprint and healthcare network. Acerus maintains control of distribution, market access, and regulatory activities on the island.
- Serum Institute of IndiacoreVerity partnered with Serum Institute of India (SIIPL), the world's largest manufacturer of vaccines, for the manufacturing and supply of VERITY-BCG (Bacillus Calmette-Guérin) for bladder cancer treatment. SIIPL manufactures BCG and supplies finished product to Verity, which markets and distributes in Canada. This partnership resolved Canada's multi-year BCG drug shortage, making Canada the first country in the western world to solve the crisis.
- DebiopharmcoreDebiopharm partnered with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar (triptorelin pamoate), a hormone therapy for prostate cancer. The agreement grants Verity Pharmaceuticals rights to commercialize Trelstar in a 20-year, extendable agreement. Trelstar is indicated for the palliative treatment of advanced prostate cancer and is a gonadotropin-releasing hormone (GnRH) agonist that works by decreasing testosterone levels.
- VygorisminorVerity entered into an exclusive Canadian licensing and supply agreement with Vygoris Ltd. (London, UK), a subsidiary of French specialist generics company Substipharm, for the supply of Mitomycin for the Canadian pharmaceutical market. Vygoris supplies the finished product and Verity markets and distributes. Mitomycin is used primarily to treat bladder cancer as well as some types of colon and stomach cancer.
- InfectoPharmmajorVerity entered into an exclusive Canadian licensing agreement with InfectoPharm (InfectoPharm Arzneimittel und Consilium GmbH) for the introduction of Intravenous Fosfomycin for the Canadian hospital market. InfectoPharm supplies the finished product while Verity markets and distributes. IVOZFO was granted priority review status by Health Canada and received Notice of Compliance in May 2019.
- PendoPharmmajorPendoPharm (division of Pharmascience Inc.) divested its rights to commercialize Zeulide Depot to Verity Pharmaceuticals. Under the agreement, Verity markets and sells Zeulide Depot (Leuprolide acetate for depot suspension) to the Canadian healthcare community. GP Pharm of Barcelona, Spain is the manufacturer of the product.
- GP PharmmajorGP Pharm of Barcelona, Spain is the owner and manufacturer of Zeulide Depot. The company specializes in injectable peptide-based products within oncology and urology using microsphere and liposome-based technological platforms for controlled depot delivery. GP Pharm developed the product from R&D through clinical studies, registration, and launch.
Scale indicators2 records
Recent moves6 records
Expansion highlights4 records
Verity Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Acerus Pharmaceuticals: Canadian specialty pharma focused on men's health (Natesto nasal testosterone gel), which Verity also promotes in Puerto Rico. Acerus competes with Verity in TRT and shares the same asset-light commercialization model targeting North American markets.
- Cumberland Pharmaceuticals: US specialty pharma that partnered with Verity for VIBATIV in Puerto Rico. Cumberland markets branded specialty hospital products through a similar lean commercial model, making it a close structural comparable.
- Lipocine: US specialty pharma that licenses TLANDO oral TRT to Verity. Lipocine focuses on men's health using proprietary drug delivery technology, sharing both therapeutic-area focus and partner-based commercialization with Verity.
- Helsinn Therapeutics: Swiss/US specialty pharma that partners with Verity for Akynzeo and Valchlor promotion in Puerto Rico. Helsinn focuses on oncology and supportive care specialty pharma, mirroring Verity's therapeutic mix and licensing-driven go-to-market approach.
- Duchesnay Inc. Canadian specialty pharma focused on women's health and specialty therapeutics. Duchesnay's Canadian base, specialty-pharma focus, and emphasis on underserved therapeutic areas align closely with Verity's Canadian heritage and specialty positioning.
- Debiopharm: Swiss specialty pharma that granted Verity 20-year exclusive US rights to Trelstar for prostate cancer. Debiopharm develops and out-licenses specialty therapeutics, sharing Verity's urology and oncology focus through a partner-based commercialization model.
- Tolmar Pharmaceuticals: US specialty pharma focused on urology and oncology (including prostate cancer treatments). Tolmar competes directly with Verity's Trelstar and Zeulide Depot in urology, serving the same urologist/oncologist customer base.
Broad incumbents
- Bausch Health Companies: Large diversified specialty pharma with broad urology, oncology, and specialty therapeutics portfolios across North America. Operates as a broad incumbent with overlapping products and the same customer segments as Verity, but at much larger scale.
- Endo International: Large specialty pharma with urology and men's health franchises (including testosterone products). Endo's specialty division competes with Verity's TRT and urology products while offering a much broader portfolio.
- Ferring Pharmaceuticals: Global specialty pharma with strong urology and reproductive health franchises. Ferring's focus on urology, prostate cancer, and specialty therapeutics overlaps with Verity's portfolio and is a potential partner or competitor for in-licensed products.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Verity Pharmaceuticals social profiles
Digital presenceVerity Pharmaceuticals compliance and trust
Trust signalCompliance2 records
Verity Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Verity Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles10 records
Verity Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Verity Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Verity Pharmaceuticals
What does Verity Pharmaceuticals do?
Verity Pharmaceuticals commercializes specialty prescription pharmaceuticals in urology, oncology, infectious disease, and men's/women's health across the US, Canada, and Puerto Rico. The company in-licenses or acquires late-stage/in-market pharmaceutical products from global manufacturers and commercializes them through a focused direct sales force targeting healthcare providers. Core products include TLANDO (oral testosterone), TRELSTAR (prostate cancer), VERITY-BCG (bladder cancer), Zeulide Depot, and IVOZFO, with additional promotional partnerships in Puerto Rico.
Is Verity Pharmaceuticals a public or private company?
Verity Pharmaceuticals is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Verity Pharmaceuticals founded?
Verity Pharmaceuticals was founded in 2016. It employs 11 to 50 people.
Where is Verity Pharmaceuticals based?
Verity Pharmaceuticals is headquartered in Mississauga, Canada, in the North America region.
How does Verity Pharmaceuticals make money?
Two revenue lines are on record. Product Licensing and Commercialization is the primary driver. The others are product Promotion Services.
Who are Verity Pharmaceuticals's main competitors?
Direct peers on record are Acerus Pharmaceuticals, Cumberland Pharmaceuticals, Lipocine, Helsinn Therapeutics, Duchesnay Inc., Debiopharm and Tolmar Pharmaceuticals. Broad incumbents are Bausch Health Companies, Endo International and Ferring Pharmaceuticals.
Does Verity Pharmaceuticals have an API?
No public API is recorded for Verity Pharmaceuticals.
What industry is Verity Pharmaceuticals in?
Verity Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAJAB, Specialty Pharmaceutical Distributors. Its NAICS code is 424210 and its SIC code is 5122.